The World Health Organization (WHO) Classification of CNS tumors, specifically CNS5, has even directly incorporated genetic modifiers, such as IDH mutations and 1p/19q codeletion, into the nomenclature of gliomas, highlighting their crucial role in the diagnosis and classification of these tumors (Louis et al., 2021). This evidence concerns the gene IDH1 and central nervous system cancer.